BioNTech 2026年4月18日 BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily 原文